研究等業績 - その他 - 藤岡 優樹
-
症例からひもとく疾患 慢性骨髄性白血病
藤岡 優樹, 永沼 綾子, 齊藤 由紀子, 植木 重治, 髙橋 直人
検査と技術 ( 株式会社医学書院 ) 53 ( 4 ) 446 - 452 2025年04月
-
急速に進行した線溶亢進型DICを伴うAMLの一例
荒井 杏子, 藤岡 優樹, 菊地 優子, 永沼 綾子, 齊藤 由紀子, 菅原 直央, 高橋 智映, 植木 重治
日臨技北日本支部医学検査学会抄録集 ( 日臨技北日本支部医学検査学会 ) 12回 103 - 103 2024年12月
-
TFR後の晩期再発は免疫の調節不全を背景にしている
藤岡 優樹, 植木 重治, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 86回 O1 - 5 2024年10月
-
好酸球ETosisにおける細胞構造の経時的変化
小玉 早穂子, 藤岡 優樹, 守時 由起, 長谷川 諒, 植木 重治
日本臨床検査医学会誌 ( (一社)日本臨床検査医学会 ) 72 ( 補冊 ) 233 - 233 2024年10月
-
慢性骨髄性白血病における無治療寛解バイオマーカーとしての制御性T細胞の表現型に関する検討
藤岡 優樹, 菅原 直央, 山本 梨絵, 高橋 智映, 守時 由起, 植木 重治
日本臨床検査医学会誌 ( (一社)日本臨床検査医学会 ) 72 ( 補冊 ) 160 - 160 2024年10月
-
自施設のESBL産生大腸菌ST131-fimH30のドラフト全ゲノム情報を用いた日本・世界株との関連性の検討
長谷川 諒, 嵯峨 知生, 安保 康太郎, 藤岡 優樹, 守時 由起, 高橋 智映, 植木 重治
日本臨床検査医学会誌 ( (一社)日本臨床検査医学会 ) 72 ( 補冊 ) 211 - 211 2024年10月
-
伊東 慶介, 藤岡 優樹, 富澤 宏基, 有馬 実咲, 安部 友恵, 守時 由起, 植木 重治
アレルギー ( (一社)日本アレルギー学会 ) 73 ( 6-7 ) 900 - 900 2024年08月
-
今月の!検査室への質問に答えます・5 アレルゲン検査で特異的IgE抗体検査と皮膚テストの比較,使い分け,注意点などを教えてください
藤岡 優樹, 嵯峨 亜希子, 植木 重治
臨床検査 ( 株式会社医学書院 ) 67 ( 6 ) 662 - 667 2023年06月
-
Endovascular Retrieval of a Fractured Tunneled Hemodialysis Central Venous Catheter Using the Loop Snare Technique.
Tomoko Sasaki, Yuki Fujioka, Haruka Hikichi, Daisuke Yokota, Shigeharu Ueki
Cureus 15 ( 2 ) e35617 2023年02月
The tunneled cuffed hemodialysis catheter is a valuable vascular access option for patients with end-stage renal disease (ESRD). Healthcare providers have become more familiar with the insertion of medical devices, including central venous catheters, in their daily practice. The occurrence of foreign body fragmentation is rare with these catheters. This article presents a case in which a fracture of the distal portion of the hemodialysis catheter was inadvertently identified during a coronary angiography. Percutaneous removal of the fractured venous catheter was performed successfully using a loop snare catheter, which prevented the patient from experiencing further complications.
-
免疫応答に着目したCMLにおけるTKI中止後の寛解維持機構の解明とバイオマーカー探索
藤岡優樹, 守時由起, 植木重治, 高橋直人
日本臨床検査医学会誌 ( (一社)日本臨床検査医学会 ) 70 ( 12 ) 944 - 948 2022年12月
-
大学検査部の研究紹介 免疫応答に着目したCMLにおけるTKI中止後の寛解維持機構の解明とバイオマーカー探索
藤岡 優樹, 高橋 直人, 守時 由起, 植木 重治
日本臨床検査医学会誌 ( (一社)日本臨床検査医学会 ) 70 ( 11 ) 899 - 899 2022年11月
-
単純型血漿交換とリツキシマブが有効であったIgM・IgG型温式抗体を有するEvans症候群
藤田 菜々子, 亀岡 吉弘, 齋藤 綾乃, 齋藤 雅也, 藤岡 優樹, 鵜生川 久美, 奈良 美保, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 63 ( 11 ) 1590 - 1590 2022年11月
-
Fujioka Y, Sugiyama D, Matsumura I, MInami Y, Miura M, Atsuta Y, Ohtake S, Kiyoi Hitoshi, Miyazaki Y, Nishikawa H, Takahashi N.
Cancers ( Cancers ) 13 ( 23 ) 5904 - 5904 2021年12月
Treatment-free remission (TFR) has become a therapeutic goal in chronic myeloid leukemia (CML), and approximately half of the patients with chronic phase-CML (CML-CP) with deep molecular remission (DMR) by tyrosine-kinase inhibitors (TKIs) have achieved TFR. However, the mechanism of continuous TFR is still unclear, as there are “fluctuate” patients who have BCR–ABL-positive leukemia cells but do not observe obvious relapse. We focused on the immune response and conducted an immune analysis using clinical samples from the imatinib discontinuation study, JALSG-STIM213. The results showed that, in the group that maintained TFR for 3 years, changes in regulatory T (Treg) cells were observed early after stopping imatinib treatment. The effector Treg (eTreg) cells increased transiently at 1 month after stopping imatinib and then returned to baseline at 3 months after stopping imatinib treatment. There was no difference in the Treg phenotype, and CD8+ T cells in the TFR group were relatively activated. High concentrations of imatinib before stopping were negatively correlated with eTreg cells after stopping imatinib. These data suggest immunological involvement in the maintenance of the TFR, and that Treg cells after stopping imatinib might be a biomarker for TFR. Furthermore, high imatinib exposure may have a negative immunological impact on the continuous TFR.
-
MYCの転座相手が非IgHと考えられるdouble hit lymphoma
安田 拓人, 亀岡 吉弘, 橋本 眞子, 藤岡 優樹, 斎藤 雅也, 鵜生川 久美, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 62 ( 9 ) 1417 - 1418 2021年09月
-
Nozaki K.
International Journal of Hematology ( International Journal of Hematology ) 113 ( 5 ) 772 - 774 2021年05月
-
Ito F, Miura M, Fujioka Y, Abumiya M, Kobayashi T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N.
International Journal of Hematology ( International Journal of Hematology ) 113 ( 1 ) 100 - 105 2021年01月
Nilotinib is a substrate of the breast cancer resistance protein (BCRP), which is a drug efflux transporter encoded by ABCG2 and regulates the pharmacokinetics of its substrates. We investigated the interaction between nilotinib and BCRP in chronic myeloid leukemia (CML) cells. An imatinib-resistant K562 cell line (K562/IM-R) treated with nilotinib was analyzed for BCRP expression, proliferation, apoptosis, and intracellular nilotinib concentration. K562/IM-R cells cultured with tyrosine kinase inhibitors (TKIs) showed an increased cell count and retained viability, whereas the growth of parental K562 cells was severely inhibited, suggesting that BCRP is involved in developing resistance to TKIs. Nilotinib-treated K562/IM-R cells showed a reduction in apoptosis; however, febuxostat pretreatment resulted in increased apoptosis. The intracellular concentration of nilotinib in K562/IM-R cells was significantly reduced compared to that in parental K562 cells, and febuxostat-pretreated K562/IM-R cells showed an increased intracellular nilotinib level compared to cells without pretreatment. The reduction in nilotinib levels caused by BCRP in CML cells might play a crucial role in resistance to TKIs. Moreover, febuxostat, as a BCRP inhibitor, could enhance nilotinib sensitivity, and combination therapy with nilotinib and febuxostat may represent a promising strategy for treatment of CML.
-
R-CHOP療法に奏効しているGCB typeのdouble expressor lymphoma(DEL)
山田 雅浩, 亀岡 吉弘, 鵜生川 久美, 齋藤 綾乃, 藤岡 優樹, 池田 翔, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 61 ( 4 ) 419 - 419 2020年04月
-
PCd療法により維持透析を離脱し完全寛解を達成したpenta-refractory IgD-λ型多発性骨髄腫
池田 翔, 山田 雅浩, 黒木 航, 齋藤 綾乃, 藤岡 優樹, 鵜生川 久美, 亀岡 吉弘, 高橋 直人
臨床血液 ( (一社)日本血液学会-東京事務局 ) 61 ( 4 ) 420 - 420 2020年04月
-
コントロール不良な高齢発症関節リウマチに後天性血友病を合併した一例
今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 藤岡 優樹, 奈良 瑞穂, 郭 永梅, 奈良 美保, 小澤 政豊, 吉岡 智子, 小松田 敦, 高橋 直人
日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 ) 29回 86 - 86 2019年11月
-
免疫プロファイリングによる、濾胞性リンパ腫の予後予測(Immune profiling analysis for prediction of outcome in patients with folliclular lymphoma)
山内 寛彦, 湯田 淳一朗, 藤岡 優樹, 長崎 譲慈, 山崎 美貴, 冨樫 庸介, 南 陽介, 西川 博嘉
臨床血液 ( (一社)日本血液学会-東京事務局 ) 59 ( 9 ) 1503 - 1503 2018年09月 [査読有り]
-
Doki N, Suyama M, Sasajima S, Ota J, Igarashi A, Mimura I, Morita H, Fujioka Y, Sugiyama D, Nishikawa H, Shimazu Y, Suda W, Takeshita K, Atarashi K, Hattori M, Sato E, Watakabe-Inamoto K, Yoshioka K, Najima Y, Kobayashi T, Kakihana K, Takahashi N, Sakamaki H, Honda K, Ohashi K.
Annals of Hematology ( Annals of Hematology ) 96 ( 9 ) 1517 - 1523 2017年09月
Post-transplant microbial diversity in the gastrointestinal tract is closely associated with clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, little is known about the impact of the fecal microbiota before allo-HSCT. We analyzed fecal samples approximately 2 weeks before conditioning among 107 allo-HSCT recipients between 2013 and 2015. Microbial analysis was performed using 16S rRNA gene sequencing. Operational taxonomic unit-based microbial diversity was estimated by calculating the Shannon index. Patients were classified into three groups based on the diversity index: low (<2), intermediate (2, 3), and high (>3) diversity (18 (16.8%), 48 (44.9%), and 41 (38.3%) patients, respectively). There were no significant differences in the 20-month overall survival, cumulative incidence of relapse, and non-relapse mortality among three groups. The cumulative incidence of grade II to IV acute graft-versus-host disease (aGVHD) was similar among the three groups (low 55.6%; intermediate 35.4%; high 48.8%, p = 0.339, at day 100). Furthermore, we found no differences in the cumulative incidence of grade II to IV acute gastrointestinal GVHD among the three groups (low 38.9%; intermediate 21.3%; high 24.4%, p = 0.778, at day 100). Regarding the composition of microbiota before allo-HSCT, aGVHD patients showed a significantly higher abundance of phylum Firmicutes (p < 0.01) and a lower tendency for Bacteroidetes (p = 0.106) than non-aGVHD patients. Maintenance of Bacteroidetes throughout allo-HSCT may be a strategy to prevent aGVHD.